Call Us @ 0172 - 4680800 | info@indswift.com | NSE - BSE
Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics : EMA
 
EMA has reviewed serious, disabling and potentially permanent side effects with quinolone and fluoroquinolone antibiotics given by mouth, injection or inhalation. The review incorporated the views of patients, healthcare professionals and academics presented at EMA's public hearing on fluoroquinolone and quinolone antibiotics in June 2018. EMA's human medicines committee (CHMP) has endorsed the recommendations of EMA's safety committee (PRAC) and concluded that the marketing authorisation of medicines containing cinoxacin, flumequine, nalidixic acid, and pipemidic acid should be suspended.
The CHMP confirmed that the use of the remaining fluoroquinolone antibiotics should be restricted. In addition, the prescribing information for healthcare professionals and information for patients will describe the disabling and potentially permanent side effects and advise patients to stop treatment with a fluoroquinolone antibiotic at the first sign of a side effect involving muscles, tendons or joints and the nervous system.
Restrictions on the use of fluoroquinolone antibiotics will mean that they should not be used to treat infections that might get better without treatment or are not severe (such as throat infections); to treat non-bacterial infections, e.g. non-bacterial (chronic) prostatitis; for preventing traveller's diarrhoea or recurring lower urinary tract infections (urine infections that do not extend beyond the bladder); to treat mild or moderate bacterial infections unless other antibacterial medicines commonly recommended for these infections cannot be used.
Importantly, fluoroquinolones should generally be avoided in patients who have previously had serious side effects with a fluoroquinolone or quinolone antibiotic. They should be used with special caution in the elderly, patients with kidney disease and those who have had an organ transplantation because these patients are at a higher risk of tendon injury. Since the use of a corticosteroid with a fluoroquinolone also increases this risk, combined use of these medicines should be avoided.
The CHMP opinion will now be forwarded to the European Commission, which will issue a final legally binding decision applicable in all EU countries. National authorities will enforce this decision for the fluoroquinolone and quinolone medicines authorised in their countries and they will also take other appropriate measures to promote the correct use of these antibiotics.

(Rxpharmatutor)
 
Other Related News:
Researchers develop reversible antiplatelet therapy to fight clotting, cancer metastasis
New insight into cell receptors opens the way for tailored cancer drugs
Pricing concerns will be the leading roadblock for pharma growth in 2019
Scientists develop tool to measure success of HIV cure strategies
High blood pressure linked to zinc deficiency
Generic Version of Popular Asthma Inhaler Wins FDA Approval
Beware of evening stress
Severe shortage of antibiotic eye drops & vitamin C tablets across India as these products brought under price control
Oncolytics Biotech initiates phase 2 study combining Pelareorep and Keytruda in advanced pancreatic cancer
NIH scientists illuminate causes of hepatitis b virus-associated acute liver failure